Resources Repository
-
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | North America | Policy/Regulation | Benefit-Cost Analysis | Infectious Diseases | Government/Law -
ArticlePublication 2020COVID-19 Infodemic: A New Front for Information Professionals
COVID-19 emerged from Wuhan, China and has spread in 213 countries, areas, or territories around …
COVID-19 emerged from Wuhan, China and has spread in 213 countries, areas, or territories around the globe, with nearly 144,683 deaths worldwide as-of April 18, 2020. In the wake of the COVID-19 pandemic, we have witnessed a massive infodemic with the public being bombarded with vast quantities of information, much of which is not scientifically correct. Fighting fake news is now the new front in the COVID-19 battle. This article comments on the role of…
Preferences/Values | Global | Policy/Regulation | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2021Correct COVID-19 Vaccine Misinformation: Lancet Commission on COVID-19 Vaccines & Therapeutics Task Force Members
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 …
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 vaccines. In 2020, up to one-third or more of people surveyed both globally and in the U.S. indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted.…
Preferences/Values | Global | Policy/Regulation | Infectious Diseases | Social Determinants | Global Governance | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Priority Setting/Ethics | North America | Policy/Regulation | Health Outcomes | Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Health/Medicine -
Online LearningVideo, Teaching Resource 2020Valuing Statistical Lives: Concepts, Current Practices, and Challenges
Many policies aim to improve longevity, decreasing the risk of death in each year, and …
Many policies aim to improve longevity, decreasing the risk of death in each year, and the value of these risk reductions often dominate the estimated benefits of risk regulations and other policies. This value is often expressed as the value per statistical life (VSL), a term that is widely misunderstood. It is not the value that the analyst, the government, or the individual places on saving an identified life with certainty. Instead, it reflects individuals’…
Global | Policy/Regulation | Benefit-Cost Analysis | Climate/Environment | Health/Medicine -
ArticlePublication 2018Consequences of a Cigarette Price Increase in 13 Middle Income Countries
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in …
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in market prices of cigarettes on health, poverty, and financial protection for men in 13 middle income countries. A 50% increase in cigarette prices would lead to about 450 million years of life gained across the 13 countries from smoking cessation, with half of these in China. Across all countries, men in the bottom income group would gain 6.7 times more…
Priority Setting/Ethics | Global | Policy/Regulation | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Health/Medicine -
BookPublication 2019Non-Communicable Disease Prevention: Best Buys, Wasted Buys, Contestable Buys
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these …
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these deaths occur in low- and middle-income countries. This book provides practical guidelines and lessons learned through real-world case studies. It is intended to be informative to NCD program managers, policy officers and decision-makers in low- and middle-income countries, who need to comparatively assess interventions for the prevention and control of NCDs.The authors emphasize the importance of context in NCD control…
Priority Setting/Ethics | Global | Policy/Regulation | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine -
Teaching PackPublication, Teaching Resource 2022Teaching Pack: Extended Cost-Effectiveness Analysis
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended …
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended cost-effectiveness analysis (ECEA) and detailing how it is conducted, and assembles ECEA publications and teaching materials. In addition to the videos, this teaching pack includes a glossary and tutorial. Videos include: Video 1. Introduction to ECEA (~2 min) Video 2. Quantifying Health Benefits (~4 min) Video 3. Private Expenditures Averted (~3 min) Video 4. Financial Risk Protection (~5 min) Video 5.…
Priority Setting/Ethics | Global | Policy/Regulation | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Economics/Finance | Health/Medicine -
Resource PortalWeb Portal, Teaching Resource 2021Disease Control Priorities (DCP3)
DCP3 includes a comprehensive review of the efficacy, effectiveness, and cost-effectiveness of priority health interventions …
DCP3 includes a comprehensive review of the efficacy, effectiveness, and cost-effectiveness of priority health interventions with the goal of influencing program design and resource allocation at global and country levels. DCP3 includes nine individual volumes, with the first eight structured around packages of conceptually related interventions, and the ninth providing an overview of main findings. Publicly available resources include journal articles and reports, both DCP3 and non-DCP3 related, as well as presentations, working papers, and book…
Priority Setting/Ethics | Global | Policy/Regulation | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Health Systems | Health/Medicine | Science/Technology | High School | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation